Case report: Durable response to alectinib in ALK-rearranged lung adenocarcinoma with acquired, crizotinib-resistant ALK C1156F mutation

被引:0
|
作者
Rao, Chuangzhou [1 ]
Nie, Liangqin [1 ]
Wu, Xiaokang [2 ]
Miao, Xiaobo [1 ]
Chen, Ting [1 ]
Chen, Liuxi [1 ]
Zhang, Dongqing [2 ]
Lin, Quan [2 ]
机构
[1] Univ Chinese Acad Sci, Hwamei Hosp, Dept Radiotherapy & Chemotherapy, Ningbo, Peoples R China
[2] Wenzhou Med Univ, Dept Resp & Crit Care Med, Affiliated Hosp 1, Wenzhou, Peoples R China
来源
FRONTIERS IN ONCOLOGY | 2022年 / 12卷
基金
浙江省自然科学基金;
关键词
non-small cell lung cancer; ALK C1156; crizotinib; alectinib; acquired resistance;
D O I
10.3389/fonc.2022.915502
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Treatment of ALK-rearranged non-small cell lung cancer (NSCLC) with tyrosine kinase inhibitors (TKIs) is challenged by the almost inevitable emergence of therapeutic resistance. Different profiles of resistance mechanisms have been reported for the currently available ALK TKIs. The ALK C1156Y mutation is reported in 2% of patients with acquired resistance to crizotinib. A rare substitution at the same site, C1156F, remains largely unknown. Existing evidence includes identification of C1156F and G1202R in an alectinib-resistant patient and sensitivity to crizotinib and resistance to later-generation 3ALK inhibitors in preclinical models. In this report, we present two cases in which NSCLC patients acquired the ALK C1156F mutation on crizotinib monotherapy. Both patients were men, and one had been heavily treated with chemotherapeutic regimens before identification of ALK rearrangement, whereas the other received crizotinib as first-line treatment. Genomic profiling of blood biopsies after progression on crizotinib suggested emergence of the ALK C1156F variant. Both patients subsequently received and responded favorably to alectinib, achieving respective progression-free survival of 21 and 15 months as of the latest follow-ups. To the best of our knowledge, this work is the first to provide clinical evidence of resistance to crizotinib and sensitivity to alectinib in NSCLC patients harboring acquired ALK C1156F mutation.
引用
收藏
页数:6
相关论文
共 50 条
  • [41] Rapid response to fifth-line brigatinib plus entrectinib in an ALK-rearranged lung adenocarcinoma with an acquired ETV6-NTRK3 fusion: a case report
    Li, Dan
    Zhu, Yue
    Song, Jincheng
    Yang, Dafu
    Cui, Saiqiong
    Liu, Xin
    Wang, Le
    Zhang, Jiangyan
    Pan, Evenki
    Dai, Zhaoxia
    [J]. FRONTIERS IN ONCOLOGY, 2024, 14
  • [42] Crizotinib rechallenge reverses MET amplification-mediated resistance to ALK inhibitors in a patient with advanced ALK-rearranged non-small cell lung cancer: a case report
    Wang, Rixiang
    Chen, Weizhuang
    Jiao, Wenrui
    Ren, Feng
    Wu, Hongcheng
    Wu, Shibo
    [J]. INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE, 2020, 13 (08): : 6163 - 6167
  • [43] Case Report: A Case Report of a Histological Transformation of ALK-Rearranged Adenocarcinoma With High Expression of PD-L1 to Squamous Cell Carcinoma After Treatment With Alectinib
    Zhang, Yan
    Qin, Yaping
    Xu, Hongen
    Yao, Qihui
    Gao, Yalan
    Feng, Yushu
    Ren, Jingli
    [J]. PATHOLOGY & ONCOLOGY RESEARCH, 2021, 27
  • [44] Remarkable Clinical Response of ALK-Rearranged/ TP53-Mutant Lung Adenocarcinoma with Liver Metastasis to Atezolizumab-Bevacizumab-Carboplatin-Paclitaxel After ALK Inhibitors: A Case Report
    Iso, Hirokazu
    Miyanaga, Akihiko
    Kadoma, Naohiro
    Shinbu, Kaoruko
    Tozuka, Takehiro
    Murata, Akari
    Nishima, Shunichi
    Sato, Yozo
    Nakamichi, Shinji
    Matsumoto, Masaru
    Noro, Rintaro
    Terasaki, Yasuhiro
    Kubota, Kaoru
    Seike, Masahiro
    [J]. ONCOTARGETS AND THERAPY, 2023, 16 : 465 - 470
  • [45] Pathological complete response to neoadjuvant ceritinib of a crizotinib-resistant, stage IIIB non-small cell lung cancer with ALK rearrangement: A case report
    Bing, Zhongxing
    Jia, Ziqi
    Wang, Yadong
    Xue, Jianchao
    Cao, Lei
    Cao, Zhili
    Liu, Peng
    Li, Ji
    Liang, Naixin
    Li, Shanqing
    [J]. THORACIC CANCER, 2021, 12 (14) : 2130 - 2133
  • [46] Novel-Acquired KANK1-ALK Fusion in An Advanced Lung Adenocarcinoma Responds to Alectinib: A Case Report
    Tang, Q.
    Xu, S.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S673 - S674
  • [47] Case Report: Identification of Two Rare Fusions, PDK1-ALK and STRN-ALK, That Coexist in a Lung Adenocarcinoma Patient and the Response to Alectinib
    Zeng, Hao
    Li, Yalun
    Wang, Ye
    Huang, Meijuan
    Zhang, Yan
    Tian, Panwen
    Li, Weimin
    [J]. FRONTIERS IN ONCOLOGY, 2021, 11
  • [48] Coexistence of a novel NBEA-ALK, EML4-ALK double-fusion in a lung adenocarcinoma patient and response to alectinib: A case report
    Liang, Qi
    Xu, Huanhuan
    Liu, Yiqian
    Zhang, Weiming
    Sun, Chongqi
    Hu, Meng
    Zhu, Yizhi
    Tan, Shanyue
    Xu, Xian
    Wang, Sumeng
    Liu, Lingxiang
    [J]. LUNG CANCER, 2021, 162 : 86 - 89
  • [49] A CASE OF LUNG ADENOCARCINOMA HARBORING BOTH A KRAS MUTATION AND AN EML4-ALK FUSION GENE WITH RESPONSE TO CRIZOTINIB
    Menefee, Michael E.
    D'Amico, Thomas A.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S1315 - S1316
  • [50] Identification of triple gene fusion ALK-LRRN2, LTBP1-ALK, and HIP1-ALK in advanced lung adenocarcinoma and response to alectinib A case report
    Ning, Shangkun
    Shi, Congcong
    Zhang, Huifang
    Li, Jinpeng
    [J]. MEDICINE, 2021, 100 (51)